ethotoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiepileptics, hydantoin derivatives 1088 86-35-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethotoin
  • accenon
  • peganone
Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.
  • Molecular weight: 204.23
  • Formula: C11H12N2O2
  • CLOGP: 1.48
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.41
  • ALOGS: -1.93
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 22, 1957 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AB01 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Hydantoin derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
CHEBI has role CHEBI:35623 anticonvulsants
MeSH PA D000927 Anticonvulsants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
FDA EPC N0000175753 Anti-epileptic Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tonic-clonic epilepsy indication 352818000 DOID:7725
Epilepsy characterized by intractable complex partial seizures indication 442481002
Suicidal thoughts contraindication 6471006
Mood swings contraindication 18963009
Lymphadenopathy contraindication 30746006
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.69 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel alpha subunit Ion channel BLOCKER CHEMBL CHEMBL

External reference:

IDSource
4018735 VUID
N0000147040 NUI
D00708 KEGG_DRUG
4018735 VANDF
C0015046 UMLSCUI
CHEBI:4888 CHEBI
CHEMBL1095 ChEMBL_ID
DB00754 DRUGBANK_ID
3292 PUBCHEM_CID
C084606 MESH_SUPPLEMENTAL_RECORD_UI
7183 IUPHAR_LIGAND_ID
660 INN_ID
46QG38NC4U UNII
204319 RXNORM
2970 MMSL
4702 MMSL
d00942 MMSL
001620 NDDF
371384002 SNOMEDCT_US
64463006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Peganone HUMAN PRESCRIPTION DRUG LABEL 1 55292-601 TABLET 250 mg ORAL NDA 12 sections
Peganone HUMAN PRESCRIPTION DRUG LABEL 1 55292-602 TABLET 250 mg ORAL NDA 12 sections